Menu

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

Taking Big Steps

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

Latest
news

02/06/2020
MorphoSys to Present at Upcoming Virtual Investor Conferences
Read Media Release
27/05/2020
MorphoSys AG Reports Outcome of Annual General Meeting 2020
Read Media Release
20/05/2020
MorphoSys and Incyte Announce the Validation of the European Marketing...
Read Media Release
14/05/2020
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual...
Read Media Release
14/05/2020
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND...
Read Media Release
06/05/2020
MorphoSys Reports First Quarter 2020 Results
Read Media Release
30/04/2020
Invitation to MorphoSys' First Quarter 2020 Results Conference Call...
Read Media Release
27/04/2020
MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial...
Read Media Release
21/04/2020
MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
Read Media Release
06/04/2020
MorphoSys Provides Update on Impact of COVID-19 on Business Operations and...
Read Media Release

June 18, 2020
Webcast
JMP Securities Hematology and Oncology Forum
virtual

Full details